



Clinical trial results:

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane

Summary

EudraCT number	2018-000222-61
Trial protocol	GB BE FR ES DE IT
Global end of trial date	

Results information

Result version number	v2
This version publication date	23 October 2025
First version publication date	09 June 2022
Version creation reason	<ul style="list-style-type: none">• New data added to full data set <p>This version is based on additional data generated at the second data cut off date of 25 July 2022. The study is still ongoing.</p>

Trial information

Trial identification

Sponsor protocol code	DS8201-A-U302
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03529110
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Daiichi Sankyo Inc.
Sponsor organisation address	211 Mt. Airy Rd., Basking Ridge, United States, 07920
Public contact	Global Clinical Director, Daiichi Sankyo Inc., 908 992-6400, CTRinfo_us@daiichisankyo.com
Scientific contact	Global Clinical Director, Daiichi Sankyo Inc., 908 992-6400, CTRinfo_us@daiichisankyo.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	25 July 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy of DS 8201a to T-DM1 as measured by progression-free survival (PFS).

Protection of trial subjects:

The study protocol, amendments, the informed consent form(s) (ICF[s]), and information sheets were approved by the appropriate and applicable Independent Ethics Committees (IECs) or Institutional Review Boards (IRBs). The study was conducted in compliance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Council for Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and applicable regulatory requirement(s).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 August 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	99 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 14
Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	Brazil: 63
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	China: 65
Country: Number of subjects enrolled	France: 38
Country: Number of subjects enrolled	Hong Kong: 21
Country: Number of subjects enrolled	Italy: 25
Country: Number of subjects enrolled	Japan: 68
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 84
Country: Number of subjects enrolled	Spain: 25
Country: Number of subjects enrolled	Taiwan: 71
Country: Number of subjects enrolled	United Kingdom: 11
Country: Number of subjects enrolled	United States: 32
Worldwide total number of subjects	524
EEA total number of subjects	93

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	418
From 65 to 84 years	106
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 524 participants were enrolled and treated across 14 countries. Following the primary results at the first data cutoff (21 May 2021), this report covers the second cutoff (25 July 2022) with analysis up to 47 months. Data collection is ongoing; further results will be shared at the next cutoff and upon study completion.

Pre-assignment

Screening details:

A total of 699 participants were screened and 524 participants enrolled in the Full Analysis Set; 6 participants did not receive treatment resulting in 518 participants in Safety Analysis Set

Period 1

Period 1 title	DCO 25 July 2022 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Trastuzumab Deruxtecan (T-DXd)

Arm description:

Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).

Arm type	Experimental
Investigational medicinal product name	trastuzumab deruxtecan
Investigational medicinal product code	
Other name	T-DXd, DS-8201a, Enhertu®
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.

Arm title	Ado-trastuzumab Emtansine (T-DM1)
------------------	-----------------------------------

Arm description:

Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.

Arm type	Experimental
Investigational medicinal product name	ado-trastuzumab emtansine
Investigational medicinal product code	
Other name	T-DM1, KADCYLA®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The treatment will be in accordance with the approved label.

Number of subjects in period 1	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)
Started	261	263
Completed	75	18
Not completed	186	245
Clinical progression	5	14
Physician decision	2	8
Other	6	6
Death	4	4
Adverse event	54	21
Randomized but not Treated	4	2
Progressive disease	94	178
Withdrawal by subject	17	12

Baseline characteristics

Reporting groups

Reporting group title	Trastuzumab Deruxtecan (T-DXd)
Reporting group description:	
Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).	
Reporting group title	Ado-trastuzumab Emtansine (T-DM1)
Reporting group description:	
Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.	

Reporting group values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)	Total
Number of subjects	261	263	524
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	212	206	418
From 65-84 years	41	49	90
85 years and over	8	8	16
Age continuous			
Units: years			
median	54.5	54.2	-
standard deviation	± 11.11	± 11.84	-
Gender categorical			
Units: Subjects			
Female	260	262	522
Male	1	1	2
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	152	162	314
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	10	9	19
White	71	72	143
More than one race	2	0	2
Unknown or Not Reported	26	20	46

End points

End points reporting groups

Reporting group title	Trastuzumab Deruxtecan (T-DXd)
Reporting group description: Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).	
Reporting group title	Ado-trastuzumab Emtansine (T-DM1)
Reporting group description: Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.	

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

End point title	Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane ^[1]
-----------------	---

End point description:

Progression-free survival (PFS) by BICR was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 25 Jul 2022.

End point type	Primary
End point timeframe: Up to 47 months (data cut-off)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was performed

End point values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261	263		
Units: months				
median (confidence interval 95%)	28.8 (22.4 to 37.9)	6.8 (5.6 to 8.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

End point title	Overall Survival (OS) in Participants With HER2-Positive,
-----------------	---

End point description:

Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. Overall survival (OS) was assessed in the Full Analysis Set at data cut-off date of 25 Jul 2022.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 47 months (data cut-off)

End point values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261 ^[2]	263 ^[3]		
Units: months				
median (confidence interval 95%)	99.9 (40.5 to 99.9)	99.9 (34.0 to 99.9)		

Notes:

[2] - 99.9=NA, Median and Upper CI was not estimable due to insufficient number of events.

[3] - 99.9=NA, Median and Upper CI was not estimable due to insufficient number of events.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

End point title	Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
-----------------	---

End point description:

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR is reported. Objective response rate was assessed in the Full Analysis Set at data cut-off date of 25 Jul 2022.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 47 months (data cut-off)

End point values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261	263		
Units: Percentage of Participants				
number (confidence interval 95%)				
BICR	78.5 (73.1 to 83.4)	35.0 (29.2 to 41.1)		
Investigator Assessment	78.9 (73.5 to 83.7)	36.9 (31.0 to 43.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

End point title	Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
-----------------	--

End point description:

Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported. Duration of Response (DoR) was assessed in the Full Analysis Set of participants with confirmed CR/PR at data cut-off date of 25 Jul 2022

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 47 months (data cut-off)

End point values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261 ^[4]	263		
Units: months				
median (confidence interval 95%)				
BICR	36.6 (22.4 to 99.9)	23.8 (12.6 to 34.7)		
Investigator Assessment	30.4 (23.0 to 99.9)	17.0 (14.1 to 24.2)		

Notes:

[4] - 99.9=NA, Upper CI was not estimable due to insufficient number of events.

Statistical analyses

Secondary: Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

End point title	Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
-----------------	--

End point description:

Progression-free survival (PFS) by investigator assessment was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 25 Jul 2022.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 47 months (data cut-off)

End point values	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	261 ^[5]	263		
Units: months				
median (confidence interval 95%)	29.1 (23.7 to 99.9)	7.2 (6.8 to 8.3)		

Notes:

[5] - 99.9=NA, Upper CI was not estimable due to insufficient number of events.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, to the data cut off date of 25 Jul 2022, up to 47 months.

Adverse event reporting additional description:

A Treatment-emergent adverse event (TEAE) is defined as an AE that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25
--------------------	----

Reporting groups

Reporting group title	Trastuzumab Deruxtecan (T-DXd)
-----------------------	--------------------------------

Reporting group description:

Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W)

Reporting group title	Ado-trastuzumab Emtansine (T-DM1)
-----------------------	-----------------------------------

Reporting group description:

Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.

Serious adverse events	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)	
Total subjects affected by serious adverse events			
subjects affected / exposed	65 / 257 (25.29%)	58 / 261 (22.22%)	
number of deaths (all causes)	72	97	
number of deaths resulting from adverse events	6	6	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			

subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiodysplasia			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial haemorrhage			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Epidural blood patch			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	4 / 257 (1.56%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Disease progression			
subjects affected / exposed	3 / 257 (1.17%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 3	0 / 1	
Oedema peripheral			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fatigue			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait inability			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	0 / 257 (0.00%)	2 / 261 (0.77%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Interstitial lung disease			
subjects affected / exposed	5 / 257 (1.95%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	5 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	4 / 257 (1.56%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal cyst			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypoxia			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			

Ejection fraction decreased			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	0 / 257 (0.00%)	3 / 261 (1.15%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy lymph gland			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical condition abnormal			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural			

complications			
Femur fracture			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation necrosis			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain herniation			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			

subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation pneumonitis			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Epilepsy			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic neuritis			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			

subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 257 (0.78%)	3 / 261 (1.15%)	
occurrences causally related to treatment / all	2 / 2	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Otolithiasis			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			

Rhegmatogenous retinal detachment subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	5 / 257 (1.95%)	2 / 261 (0.77%)	
occurrences causally related to treatment / all	6 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			

subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric perforation			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Jaundice cholestatic			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic atrophy			

subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endocrine disorders			
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone lesion			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis of jaw			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations			
Pneumonia			
subjects affected / exposed	5 / 257 (1.95%)	6 / 261 (2.30%)	
occurrences causally related to treatment / all	3 / 6	2 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	3 / 257 (1.17%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 257 (0.39%)	4 / 261 (1.53%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Breast cellulitis			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	1 / 257 (0.39%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Soft tissue infection			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			

subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 257 (0.78%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia fungal			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	2 / 257 (0.78%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			

subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	1 / 257 (0.39%)	0 / 261 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 257 (0.00%)	2 / 261 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency			
subjects affected / exposed	0 / 257 (0.00%)	1 / 261 (0.38%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Trastuzumab Deruxtecan (T-DXd)	Ado-trastuzumab Emtansine (T-DM1)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	254 / 257 (98.83%)	247 / 261 (94.64%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	16 / 257 (6.23%)	8 / 261 (3.07%)	
occurrences (all)	25	8	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	79 / 257 (30.74%)	52 / 261 (19.92%)	
occurrences (all)	159	70	
Asthenia			

subjects affected / exposed occurrences (all)	37 / 257 (14.40%) 72	31 / 261 (11.88%) 59	
Malaise subjects affected / exposed occurrences (all)	30 / 257 (11.67%) 70	9 / 261 (3.45%) 9	
Pyrexia subjects affected / exposed occurrences (all)	37 / 257 (14.40%) 65	42 / 261 (16.09%) 75	
Oedema peripheral subjects affected / exposed occurrences (all)	23 / 257 (8.95%) 25	10 / 261 (3.83%) 10	
Influenza like illness subjects affected / exposed occurrences (all)	18 / 257 (7.00%) 26	6 / 261 (2.30%) 7	
Respiratory, thoracic and mediastinal disorders Epistaxis subjects affected / exposed occurrences (all)	35 / 257 (13.62%) 57	46 / 261 (17.62%) 73	
Cough subjects affected / exposed occurrences (all)	40 / 257 (15.56%) 51	29 / 261 (11.11%) 34	
Dyspnoea subjects affected / exposed occurrences (all)	22 / 257 (8.56%) 33	16 / 261 (6.13%) 18	
Oropharyngeal pain subjects affected / exposed occurrences (all)	14 / 257 (5.45%) 17	7 / 261 (2.68%) 8	
Interstitial lung disease subjects affected / exposed occurrences (all)	13 / 257 (5.06%) 14	2 / 261 (0.77%) 2	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	21 / 257 (8.17%) 23	6 / 261 (2.30%) 6	
Insomnia			

subjects affected / exposed occurrences (all)	20 / 257 (7.78%) 24	26 / 261 (9.96%) 26	
Investigations			
Neutrophil count decreased			
subjects affected / exposed	79 / 257 (30.74%)	30 / 261 (11.49%)	
occurrences (all)	426	63	
Aspartate aminotransferase increased			
subjects affected / exposed	72 / 257 (28.02%)	107 / 261 (41.00%)	
occurrences (all)	162	157	
White blood cell count decreased			
subjects affected / exposed	60 / 257 (23.35%)	16 / 261 (6.13%)	
occurrences (all)	325	32	
Alanine aminotransferase increased			
subjects affected / exposed	59 / 257 (22.96%)	82 / 261 (31.42%)	
occurrences (all)	130	112	
Platelet count decreased			
subjects affected / exposed	64 / 257 (24.90%)	114 / 261 (43.68%)	
occurrences (all)	148	198	
Blood alkaline phosphatase increased			
subjects affected / exposed	40 / 257 (15.56%)	34 / 261 (13.03%)	
occurrences (all)	57	60	
Blood lactate dehydrogenase increased			
subjects affected / exposed	24 / 257 (9.34%)	36 / 261 (13.79%)	
occurrences (all)	42	61	
Blood bilirubin increased			
subjects affected / exposed	22 / 257 (8.56%)	13 / 261 (4.98%)	
occurrences (all)	48	28	
Lymphocyte count decreased			
subjects affected / exposed	15 / 257 (5.84%)	3 / 261 (1.15%)	
occurrences (all)	35	4	
Weight decreased			
subjects affected / exposed	58 / 257 (22.57%)	23 / 261 (8.81%)	
occurrences (all)	72	26	
Weight increased			

subjects affected / exposed	17 / 257 (6.61%)	2 / 261 (0.77%)	
occurrences (all)	17	2	
Blood creatinine increased			
subjects affected / exposed	14 / 257 (5.45%)	3 / 261 (1.15%)	
occurrences (all)	31	7	
Gamma-glutamyltransferase increased			
subjects affected / exposed	12 / 257 (4.67%)	17 / 261 (6.51%)	
occurrences (all)	16	17	
Electrocardiogram QT prolonged			
subjects affected / exposed	11 / 257 (4.28%)	15 / 261 (5.75%)	
occurrences (all)	20	25	
Nervous system disorders			
Headache			
subjects affected / exposed	61 / 257 (23.74%)	40 / 261 (15.33%)	
occurrences (all)	92	54	
Dizziness			
subjects affected / exposed	37 / 257 (14.40%)	25 / 261 (9.58%)	
occurrences (all)	50	28	
Peripheral sensory neuropathy			
subjects affected / exposed	20 / 257 (7.78%)	25 / 261 (9.58%)	
occurrences (all)	22	28	
Dysgeusia			
subjects affected / exposed	16 / 257 (6.23%)	9 / 261 (3.45%)	
occurrences (all)	19	9	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	94 / 257 (36.58%)	50 / 261 (19.16%)	
occurrences (all)	219	108	
Neutropenia			
subjects affected / exposed	44 / 257 (17.12%)	8 / 261 (3.07%)	
occurrences (all)	119	33	
Leukopenia			
subjects affected / exposed	29 / 257 (11.28%)	9 / 261 (3.45%)	
occurrences (all)	63	23	
Lymphopenia			

subjects affected / exposed	21 / 257 (8.17%)	10 / 261 (3.83%)	
occurrences (all)	53	18	
Thrombocytopenia			
subjects affected / exposed	17 / 257 (6.61%)	36 / 261 (13.79%)	
occurrences (all)	34	60	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	15 / 257 (5.84%)	5 / 261 (1.92%)	
occurrences (all)	19	6	
Eye disorders			
Dry eye			
subjects affected / exposed	13 / 257 (5.06%)	10 / 261 (3.83%)	
occurrences (all)	13	10	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	196 / 257 (76.26%)	79 / 261 (30.27%)	
occurrences (all)	660	107	
Vomiting			
subjects affected / exposed	131 / 257 (50.97%)	27 / 261 (10.34%)	
occurrences (all)	309	34	
Constipation			
subjects affected / exposed	95 / 257 (36.96%)	50 / 261 (19.16%)	
occurrences (all)	167	59	
Diarrhoea			
subjects affected / exposed	83 / 257 (32.30%)	20 / 261 (7.66%)	
occurrences (all)	176	29	
Dyspepsia			
subjects affected / exposed	31 / 257 (12.06%)	16 / 261 (6.13%)	
occurrences (all)	34	16	
Abdominal pain			
subjects affected / exposed	36 / 257 (14.01%)	6 / 261 (2.30%)	
occurrences (all)	43	8	
Abdominal pain upper			
subjects affected / exposed	30 / 257 (11.67%)	14 / 261 (5.36%)	
occurrences (all)	42	15	
Gastrooesophageal reflux disease			

subjects affected / exposed occurrences (all)	14 / 257 (5.45%) 17	5 / 261 (1.92%) 5	
Stomatitis subjects affected / exposed occurrences (all)	46 / 257 (17.90%) 63	10 / 261 (3.83%) 12	
Abdominal distension subjects affected / exposed occurrences (all)	13 / 257 (5.06%) 60	6 / 261 (2.30%) 6	
Dry mouth subjects affected / exposed occurrences (all)	9 / 257 (3.50%) 15	26 / 261 (9.96%) 28	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	102 / 257 (39.69%) 119	9 / 261 (3.45%) 10	
Pruritus subjects affected / exposed occurrences (all)	23 / 257 (8.95%) 28	19 / 261 (7.28%) 23	
Rash subjects affected / exposed occurrences (all)	18 / 257 (7.00%) 23	24 / 261 (9.20%) 27	
Dry skin subjects affected / exposed occurrences (all)	15 / 257 (5.84%) 16	5 / 261 (1.92%) 5	
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	26 / 257 (10.12%) 33	15 / 261 (5.75%) 16	
Myalgia subjects affected / exposed occurrences (all)	26 / 257 (10.12%) 33	17 / 261 (6.51%) 25	
Arthralgia subjects affected / exposed occurrences (all)	41 / 257 (15.95%) 50	38 / 261 (14.56%) 42	
Pain in extremity			

subjects affected / exposed	24 / 257 (9.34%)	21 / 261 (8.05%)	
occurrences (all)	27	27	
Muscle spasms			
subjects affected / exposed	12 / 257 (4.67%)	16 / 261 (6.13%)	
occurrences (all)	18	17	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	21 / 257 (8.17%)	15 / 261 (5.75%)	
occurrences (all)	37	16	
Pneumonia			
subjects affected / exposed	15 / 257 (5.84%)	5 / 261 (1.92%)	
occurrences (all)	16	5	
Pneumonitis			
subjects affected / exposed	21 / 257 (8.17%)	3 / 261 (1.15%)	
occurrences (all)	26	3	
Upper respiratory tract infection			
subjects affected / exposed	23 / 257 (8.95%)	16 / 261 (6.13%)	
occurrences (all)	28	18	
COVID-19			
subjects affected / exposed	23 / 257 (8.95%)	8 / 261 (3.07%)	
occurrences (all)	24	8	
Nasopharyngitis			
subjects affected / exposed	14 / 257 (5.45%)	7 / 261 (2.68%)	
occurrences (all)	16	9	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	77 / 257 (29.96%)	46 / 261 (17.62%)	
occurrences (all)	202	55	
Hypokalaemia			
subjects affected / exposed	39 / 257 (15.18%)	29 / 261 (11.11%)	
occurrences (all)	107	52	
Hypoalbuminaemia			
subjects affected / exposed	24 / 257 (9.34%)	14 / 261 (5.36%)	
occurrences (all)	55	35	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 June 2018	Clarified TEAEs section. Updated dose information & modification section and inclusion & exclusion criteria section. Updated definitions of Grade 2, 3, and 4 for specific investigations. Clarified language for timing of signed and dated written consent. Clarified details of urine pregnancy test results. Clarified details of lab procedures. Added details for PK sampling.
08 March 2019	Clarified the primary objective and updated secondary endpoints. Updated inclusion and exclusion criteria. Updated and clarified AE reporting and follow-up. Updated dose modification, screening, and lab sections. Updated PK sampling times. Updated procedures section.
26 April 2019	Clarified interstitial lung disease information.
23 April 2020	Added additional analyses of PFS and OS. Updated the secondary endpoint of OS. Updated the exploratory endpoints. Updated inclusion & exclusion criteria section. Updated general statistical considerations and dose modification sections. Updated screening and lab procedures. Clarified the PK sampling and end of treatment timing. Updated AE of Special Interest. Updated the Schedule of Events section.
25 September 2020	Updated to incorporate the COVID-19 management procedures. Updated exploratory endpoints to include PFS on next line therapy. Clarified withdrawal of consent language.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported